Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers

(2015) Janos L. Tanyi et al.   CANCER RESEARCH

Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

(2015) Dung T. Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

(2015) S S Kenderian et al.   LEUKEMIA

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

(2015) G. K. Pennock et al.   ONCOLOGIST

High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis

(2015) Anish Thomas et al.   Oncotarget

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen

(2014) Raffit Hassan et al.   CANCER

Abstract LB-291: First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.

(2014) Johanna Bendell et al.   CANCER RESEARCH

Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy

(2014) I. Pastan et al.   CANCER RESEARCH

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma

(2014) R. Hassan et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

(2014) C. M. Lovly et al.   CLINICAL CANCER RESEARCH

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors

(2014) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

(2014) S. Golfier et al.   MOLECULAR CANCER THERAPEUTICS

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expansion of Anti-Mesothelin Specific CD4+ and CD8+ T Cell Responses in Patients with Pancreatic Carcinoma

(2014) Yuan Chen et al.   PLoS One

Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival

(2014) Gary Tozbikian et al.   PLoS One

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment

(2014) Gregory L Beatty et al.   OncoImmunology

Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma

(2013) S. S. Kachala et al.   CLINICAL CANCER RESEARCH

Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia

(2013) David M. Barrett et al.   HUMAN GENE THERAPY

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma

(2013) Bryan D. Choi et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

(2013) Dung T. Le et al.   JOURNAL OF IMMUNOTHERAPY

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

(2013) Cor HJ Lamers et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma

(2013) Lihua E. Budde et al.   PLoS One

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

(2013) R. Hassan et al.   Science Translational Medicine

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

(2013) G. L. Beatty et al.   Cancer Immunology Research

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

(2013) M. V. Maus et al.   Cancer Immunology Research

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

(2012) B. G. Till et al.   BLOOD

Mesothelin, a novel immunotherapy target for triple negative breast cancer

(2012) Julia Tchou et al.   BREAST CANCER RESEARCH AND TREATMENT

Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma

(2012) Atsushi Shimizu et al.   CANCER SCIENCE

Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients

(2012) E. L. Servais et al.   CLINICAL CANCER RESEARCH

A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma

(2011) Lutz Eric et al.   ANNALS OF SURGERY

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo

(2011) D.-G. Song et al.   BLOOD

A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

(2011) D. T. Le et al.   CLINICAL CANCER RESEARCH

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis

(2011) Wei-Ting Hwang et al.   GYNECOLOGIC ONCOLOGY

Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells

(2011) David M. Barrett et al.   HUMAN GENE THERAPY

Structural Analysis of the Cancer-specific Promoter in Mesothelin and in Other Genes Overexpressed in Cancers

(2011) Yunzhao R. Ren et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor

(2011) Evripidis Lanitis et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Co-Expression of Mesothelin and CA125 Correlates With Unfavorable Patient Outcome in Pancreatic Ductal Adenocarcinoma

(2011) Takahiro Einama et al.   PANCREAS

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells

(2010) C. H. J. Lamers et al.   BLOOD

Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor

(2010) Y. Zhao et al.   CANCER RESEARCH

Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers

(2010) R. Hassan et al.   CLINICAL CANCER RESEARCH

Mesothelial proteins are expressed in the human cornea

(2010) Katerina Jirsova et al.   EXPERIMENTAL EYE RESEARCH

Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T-Cell Receptor Gene Transfer with Lentiviral Vectors

(2009) S. Bobisse et al.   CANCER RESEARCH

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

(2009) R. J. Kreitman et al.   CLINICAL CANCER RESEARCH

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication

(2009) Xiao-Song Zhong et al.   MOLECULAR THERAPY

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

(2009) C. Carpenito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

(2008) D. Laheru et al.   CLINICAL CANCER RESEARCH

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

(2008) Salima Hacein-Bey-Abina et al.   JOURNAL OF CLINICAL INVESTIGATION

A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer

(2008) E. Kieback et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA